QUICK TAKE
The signal, without the leap.
Lilly reported that the investigational triple-receptor agonist retatrutide met the primary and key secondary endpoints in two additional Phase 3 trials. The release adds late-stage human evidence, while leaving the decisive regulatory and full-publication questions open.
WHAT CHANGED
Key points from the source.
- 01
In company-reported topline results, TRIUMPH-2 participants receiving the highest dose lost an average of 20.8% of body weight at 80 weeks under the trial's efficacy estimand.
- 02
Lilly reported an average 22.6% reduction at the highest dose in TRIUMPH-3, a trial involving people with obesity or overweight and established cardiovascular disease and/or chronic kidney disease.
- 03
The company said it plans a U.S. biologics license application submission in the first quarter of 2027.
- 04
The release is a company summary of topline results. Full results and peer-reviewed analysis are still needed to inspect methods, adverse events, subgroup findings, and limitations in detail.
WHY IT MATTERS
The decision boundary.
The two readouts move retatrutide's evidence profile further into late-stage human research and add populations with clinically important comorbidity.
They do not erase the current decision boundary: tirzepatide and semaglutide have FDA-approved products for defined indications, while retatrutide remains investigational.
PRIMARY SOURCES